Jimu News reporter Zhao Xuechun.
Correspondent Chang Yu.
Recently, led by Chen Xiaoping, academician of the Chinese Academy of Sciences and director of the Department of Surgery of Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, and jointly formulated by more than 60 domestic liver cancer research experts involving nearly 10 disciplines, the "Joint Chinese Multidisciplinary Expert Consensus on Immune Checkpoint Inhibitors for Hepatocellular Carcinoma" (hereinafter referred to as the "Consensus") was published in the internationally renowned journal "Liver Cancer".
consensus".
Chen Xiaoping introduced that in view of the insidious pathogenesis of hepatocellular carcinoma, more than 70% of Chinese liver cancer patients are unable to undergo **sexual surgery at the time of first diagnosis**. At the same time, the overall ** rate of liver cancer within 5 years after surgery is about 70%. *After that, most patients are also not candidates for surgery**. Therefore, systemic anti-tumor**, especially combination regimens based on immune checkpoint inhibitors, have become the most commonly used and important methods for patients with unresectable hepatocellular carcinoma.
In order to better help clinicians use immunotherapy rationally, effectively and safely and formulate a plan for liver cancer, Chen Xiaoping led the establishment of an editorial committee, which was revised and improved on the basis of the 2021 edition by strengthening discussions with experts in multidisciplinary fields, and formed the "Chinese Multidisciplinary Expert Consensus on Immune Checkpoint Inhibitor-based Immune Checkpoint Inhibitors" (2023 edition).
This consensus summarizes the principles and methods of clinical application of immune checkpoint inhibitors combined with hepatocellular carcinoma, including regimen selection, perioperative application, transformation, screening of suitable contraindications, efficacy evaluation and adverse reaction management. The "consensus" especially emphasizes the rational formulation of strategies according to the synergistic mechanism of different ways of liver cancer in the multidisciplinary diagnosis and treatment model, and pays attention to the operability in clinical work and the accessibility of drug regimens.
As one of the main participants, Professor Xia Feng of the Southwest Hospital of the Army Medical University said that this "consensus" adopts the Delphi consensus formation method, through anonymous opinions, multiple rounds of investigation of experts' views on issues related to the "consensus", after repeated consultation, induction, revision and statistical processing, and finally summarized into expert opinions as the result.
Chen Xiaoping said that the editorial board will continue to update and improve the "consensus" based on the latest clinical trials and evidence-based medicine data, so as to guide clinicians to extend the overall survival time of patients as much as possible and achieve more significant clinical benefits.
*: Jimu News).
For more exciting information, please contact the application market**"Jimu News" client, do not be authorized**, welcome to provide news clues, and pay once adopted.